Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Therapeutic Advances in Chronic Disease

• Publication date

  2016-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/2040622316658463PMID 27583123PMCID PMC4994396
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THE RISK OF MORTALITY

  2017cited by this paper
• The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia

  2017cited by this paper
• The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.

  2016cited by this paper
• Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis

  2015influential reference
• The Mortality Risk of Conventional Antipsychotics in Elderly Patients: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.

  2015influential reference
• Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.

  2015influential reference
• Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease

  2015cited by this paper
• Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care.

  2015cited by this paper
• Advancements in the treatment of agitation in Alzheimer’s disease

  2015cited by this paper
• Common Sense: Addressed to Geriatric Psychiatrists on the Subject of Behavioral and Psychological Symptoms of Dementia.

  2015influential reference
• A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice

  2015cited by this paper
• A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents.

  2015cited by this paper
• Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.

  2015cited by this paper
• Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

  2015cited by this paper
• Use and Safety of Antipsychotics in Behavioral Disorders in Elderly People With Dementia

  2014cited by this paper
• Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis

  2014cited by this paper
• Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials.

  2014influential reference
• Management of Neuropsychiatric Symptoms of Dementia in Clinical Settings: Recommendations from a Multidisciplinary Expert Panel

  2014influential reference
• Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis

  2014influential reference
• The Efficacy and Safety of Atypical Antipsychotics for the Treatment of Dementia: A Meta-Analysis of Randomized Placebo-Controlled Trials

  2014influential reference
• Pharmacological management of behavioral symptoms associated with dementia.

  2014cited by this paper
• Neuropsychiatric Symptoms of Dementia: Consent, Quality of Life, and Dignity

  2013cited by this paper
• Antipsychotic Discontinuation in Patients with Dementia: A Systematic Review and Meta-Analysis of Published Randomized Controlled Studies

  2013influential reference
• The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.

  2013cited by this paper
• Psychotropic Medications and the Transition Into Care: A National Data Linkage Study

  2013cited by this paper
• Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.

  2013influential reference
• Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units

  2013cited by this paper
• Use of Antipsychotics Among Older Residents in VA Nursing Homes

  2012cited by this paper
• Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life of people with dementia

  2012cited by this paper
• Risk of mortality among individual antipsychotics in patients with dementia.

  2012cited by this paper
• Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia.

  2012cited by this paper
• Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services

  2012cited by this paper
• Review: Risk of Cerebrovascular Adverse Events and Death in Elderly Patients With Dementia When Treated With Antipsychotic Medications: A Literature Review of Evidence

  2011cited by this paper
• Prescribing pattern of psychotropic drugs in nursing home residents with dementia

  2011cited by this paper
• Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.

  2011influential reference
• Antidepressants for agitation and psychosis in dementia.

  2011cited by this paper
• Role of systematic reviews and meta-analysis in evidence-based clinical practice

  2011cited by this paper
• Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials.

  2011influential reference
• Unexplained variation across US nursing homes in antipsychotic prescribing rates.

  2010cited by this paper
• Management of agitation and aggression associated with Alzheimer disease

  2009cited by this paper
• Use of physical restraints and antipsychotic medications in nursing homes: a cross‐national study

  2009cited by this paper
• Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions

  2009cited by this paper
• Efficacy of Memantine on Behavioral and Psychological Symptoms Related to Dementia: A Systematic Meta-Analysis

  2008cited by this paper
• A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)

  2008cited by this paper
• The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta‐analysis of 4 placebo‐controlled clinical trials

  2007cited by this paper
• Quetiapine for agitation or psychosis in patients with dementia and parkinsonism

  2007cited by this paper
• Meta-Analysis of the Effectiveness of Atypical Antipsychotics for the Treatment of Behavioural Problems in Persons with Dementia

  2007influential reference
• Atypical antipsychotics for aggression and psychosis in Alzheimer's disease

  2006cited by this paper
• Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.

  2006influential reference
• Role of Systematic Reviews and Meta-analysis in Evidence-based Medicine

  2005cited by this paper
• Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

  2005cited by this paper
• Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia.

  2005cited by this paper
• The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.

  2002influential reference
• Efficacy of Olanzapine in the Treatment of Psychosis in Dementia with Lewy Bodies

  2002cited by this paper
• Thioridazine for dementia.

  2001cited by this paper
• Thioridazine for dementia.

  2001influential reference
• A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia

  1990cited by this paper

• Barriers and facilitators to implementing strategies for reducing inappropriate antipsychotic use in long-term care: a scoping review.

  2026cites this paper
• Characteristics and predictors of antipsychotic medication off-label use among community-dwelling older people.

  2026cites this paper
• Multiple Adverse Outcomes Associated with Risperidone in People with Dementia: An Individual Participant Data Meta-Analysis.

  2026cites this paper
• Variation in Psychotropic and Non-Psychotropic Prescribing in Nursing Homes: A Multi-Level EMR-Based Retrospective Cohort Study.

  2026cites this paper
• Mind-body interventions to promote the mental health of older adults with cognitive impairment and dementia: a scoping review and logic model.

  2026cites this paper
• Immersive Interventions for Dementia: A Narrative Review of Virtual Reality's Role in Therapy, Well-Being, and Future Care Models

  2026cites this paper
• Disparity of Prescribed Psychotropics in Alzheimer’s Disease with Neuropsychiatric Symptoms

  2025cites this paper
• Pharmacological Interventions for Excoriation Behaviors in Alzheimer's Disease: An Empty Systematic Review of Clinical Trials

  2025cites this paper
• DEprescribing and Care to reduce Antipsychotics in DEmentia (DECADE)-A Hybrid Effectiveness-Implementation Pilot Study.

  2025cites this paper
• Psychotropic medications versus non-pharmacologic approaches for managing behavioural and psychological symptoms in Australian aged care residents with dementia: general practitioners’ and physicians’ perspectives

  2025cites this paper
• Silent nights: Adjunctive lemborexant for managing nighttime agitation and sleep disturbances in Alzheimer's dementia

  2025cites this paper
• Predictors and Moderators of Hospitalisation and Mortality in People with Dementia Using Antipsychotics: Systematic Review

  2025influential citation
• Behavioral and Psychological Symptoms (BPSD) in Alzheimer's Disease (AD): Development and Treatment.

  2025cites this paper
• Dysregulated Neurotransmitters and CB1 Receptor Dysfunction and Their Roles in Agitation Associated with Alzheimer’s Disease

  2025cites this paper
• Psychotropic Polypharmacy in Dementia: A Retrospective Analysis for People with Neuropsychiatric Symptoms Referred to an Australian Dementia Support Service

  2025cites this paper
• Improving Medication-Related Safety for Residents in Nursing Homes: A Qualitative Study.

  2025cites this paper
• Humanistic mental health strategies and antipsychotic stewardship to reduce unnecessary medications in a nursing home: A longitudinal quality improvement study

  2025cites this paper
• Prolonged Hospitalization and Adverse Events in Veterans Awaiting Guardianship: A Retrospective Cohort Analysis

  2025cites this paper
• Factors associated with length of stay in patients from residential aged care facilities admitted for behavioural and psychological symptoms of dementia

  2025cites this paper
• A Self-Explainable Dynamic Risk Monitoring Framework for Predicting Alzheimer’s Disease and Related Dementias

  2025cites this paper
• Identifying dementia neuropathology using low‐burden clinical data

  2025cites this paper
• Recent advances in symptomatic management and immunotherapies for Alzheimer's disease treatment: a narrative review

  2025cites this paper
• Variation in the potentially inappropriate use of antipsychotic and benzodiazepine medications among individuals receiving residential medication management reviews.

  2025cites this paper
• Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines.

  2025cites this paper
• Non-pharmacological interventions to reduce neuropsychiatric symptoms in hospitalised patients for behavioural crises with cognitive impairment: A systematic review.

  2025cites this paper
• Treatment modifiers and predictors of risperidone response in dementia: An individual participant data meta‐analysis of six randomized controlled trials

  2025cites this paper
• Trends of antipsychotic prescribing for people with dementia in Spain

  2025cites this paper
• Brexpiprazole for agitation in alzheimer’s disease: A systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Simultaneous modulation of 5-HT6 and SERT by MM394: a dual-target ligand providing neuroprotection against amyloid-β toxicity, memory preservation, and alleviation of BPSD symptoms.

  2025cites this paper
• Medications and cognitive decline in Alzheimer's disease: Cohort cluster analysis of 15,428 patients

  2025influential citation
• Can cannabinoids alleviate behavioral symptoms in older adults with dementia? A systematic review.

  2025cites this paper
• Association between socioeconomic status and dispensing of higher-risk drug classes and polypharmacy in older community-based populations: a nationwide cohort study

  2025cites this paper
• Psychotropic Drug Use Among Danish Care Home Residents During and After the COVID‐19 Pandemic

  2025cites this paper
• Potentially High-Risk Antipsychotic Use in People With Dementia: A National Data Linkage Study.

  2025cites this paper
• Management of antipsychotics in primary care: Insights from healthcare professionals and policy makers in the United Kingdom

  2024cites this paper
• Stratification of Alzheimer's Disease Patients Using Knowledge-Guided Unsupervised Latent Factor Clustering with Electronic Health Record Data

  2024cites this paper
• Effects of Nursing Home Changes in Antipsychotic Use on Outcomes Among Residents With Dementia.

  2024cites this paper
• Health outcomes in chronic kidney disease patients with cognitive impairment or dementia: a global collaborative analysis

  2024cites this paper
• Pharmacotherapy of restlessness in dementia

  2024cites this paper
• A Longitudinal Treatment Effect Analysis of Antipsychotics on Behavior of Residents in Long-Term Care.

  2024cites this paper
• Profiles of healthcare use of persons living with dementia: A population‐based cohort study

  2024cites this paper
• Reducing the Inappropriate Use of Antipsychotics in Long-Term Care: Strategies for Success.

  2024cites this paper
• Pimavanserin’s Safety Profile: Insights from a Phase 3b Clinical Trial

  2024cites this paper
• Recognition and assessment of pain in people with advanced dementia.

  2024cites this paper
• The Impact of Training in Multimodal Communication Skills on Psychotropic Medication Use in Dementia Care

  2024cites this paper
• Indoor Environmental Conditions and Likelihood of Reported Violence and Aggression in a Purpose-Built Residential Dementia Hospital

  2024cites this paper
• First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease

  2024cites this paper
• Antipsychotics and Risks of Cardiovascular and Cerebrovascular Diseases and Mortality in Dwelling Community Older Adults

  2024cites this paper
• Investigation of the Approaches to Optimal Exercise Interventions Based on Dementia Type: A Theoretical Review

  2024cites this paper
• Effects of Bright Light Therapy on Agitation Among Older Adults Living with Dementia in Macao: A Pilot Study

  2024cites this paper
• Physician Antipsychotic Overprescribing Letters and Cognitive, Behavioral, and Physical Health Outcomes Among People With Dementia

  2024cites this paper
• The effects of singing interventions on quality of life, mood and levels of agitation in community-dwelling people living with dementia: A quantitative systematic review

  2024cites this paper
• Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis

  2024cites this paper
• An economic evaluation of antipsychotic medications given to persons with dementia

  2024cites this paper
• Perspectives of aged care home staff and health care professionals on the Psychotropic medicines use in Residents And Culture: Influencing clinical Excellence (PRACTICE) tool ©.

  2024cites this paper
• Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation.

  2024cites this paper
• Antipsychotika: Was der Allgemeinmediziner wissen sollte

  2023cites this paper
• Epidemiology of infection, transmission and COVID-19 outcomes among mental health users and workers in a comprehensive network of long-term mental health facilities: Retrospective observational population-base study

  2023cites this paper
• Olanzapine, Risperidone and Clozapine prescribing is associated with increased risk for Alzheimers Disease reflecting antipsychotic-specific effects on microglial phagocytosis

  2023cites this paper
• Do community-based singing interventions have an impact on people living with dementia and their carers? A mixed-methods study protocol

  2023cites this paper
• Combination of Antidepressants and Antipsychotics as A Novel Treatment Option for Psychosis in Alzheimer's Disease

  2023cites this paper
• Environmental enrichment improves cognitive function, learning, memory and anxiety-related behaviours in rodent models of dementia: implications for future study.

  2023cites this paper
• Nonpharmacological tactile activity interventions for reducing behavioural and psychological symptoms of dementia in the acute hospital setting: An integrative review.

  2023cites this paper
• Adequate diagnosis of the cause of Parkinsonism and treatment in an elderly patient with schizophrenia: A case report

  2023cites this paper
• Secular Trends in Central Nervous System-Active Polypharmacy Among Serial Cross-Sections of US Adults, 2009–2020

  2023cites this paper
• Application of the Person-Centered Care to Manage Responsive Behaviors in Clients with Major Neurocognitive Disorders: A Qualitative Single Case Study

  2023cites this paper
• Understanding neuropsychiatric symptoms in Alzheimer’s disease: challenges and advances in diagnosis and treatment

  2023cites this paper
• Neuropsychiatric Manifestations in Alzheimer's Disease Patients: Genetics and Treatment Options.

  2023cites this paper
• Antipsychotic use among older patients with dementia receiving home health care services: Prevalence, predictors, and outcomes

  2023cites this paper
• Prescribing pattern of anti-psychotic medications in patients with dementia in Oman: a retrospective observational study

  2023cites this paper
• Quetiapine Oral Solution in Alzheimer’s Disease: Efficacy and Dosage Insights from a Real-World Retrospective Study

  2023cites this paper
• Psychopharmaka in der Praxis: Ein Blick auf Antipsychotika

  2023cites this paper
• Changes in Polypharmacy and Potentially Inappropriate Medications in Homebound Older Adults in Japan, 2015–2019: a Nationwide Study

  2023cites this paper
• A New Hope in Alzheimer's Disease Psychosis: Pimavanserin.

  2023cites this paper
• Policies Shaping Nursing Home Medication Practices: Involving Nurses to Advance Individualized Deprescribing.

  2023cites this paper
• Comparison of glomerular filtration rate estimating equations in older adults: A systematic review and meta-analysis.

  2023cites this paper
• Unveiling the Enigma: Exploring Risk Factors and Mechanisms for Psychotic Symptoms in Alzheimer’s Disease through Electronic Medical Records with Deep Learning Models

  2023cites this paper
• Antipsychotic Use and Mortality in Persons with Alcohol-Related Dementia or Wernicke–Korsakoff Syndrome: A Nationwide Register Study in Finland

  2023cites this paper
• Continuous Improvement of the Rational Use of Central Nervous System Disease‐Related Drugs in Elderly Inpatients

  2023cites this paper
• Analysis of Concomitant Medications Prescribed with Antipsychotics to Patients with Dementia

  2023cites this paper
• Chronic cerebral hypoperfusion: a critical feature in unravelling the etiology of vascular cognitive impairment

  2023cites this paper
• Lurasidone treatment for delusional infestation in a patient with dementia

  2023cites this paper
• Prevalences and Indications of Psychotropic Drug Prescriptions in Nursing Home Residents with Korsakoff Syndrome

  2023cites this paper
• Combination of antidepressants and antipsychotics as a novel treatment option for psychosis in Alzheimer's disease

  2023cites this paper
• Potentially Inappropriate Medication Use in Community-Dwelling Older Adults Living with Dementia

  2023cites this paper
• The value of supportive care: A systematic review of cost-effectiveness of non-pharmacological interventions for dementia

  2023cites this paper
• Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: A systematic review and network meta-analysis

  2023cites this paper
• Acute Antipsychotic Use and Presence of Dysphagia Among Older Veterans With Heart Failure.

  2023cites this paper
• Psychotropic Medication Prescribing to Patients with Dementia Admitted to Acute Hospitals in Ireland

  2023cites this paper
• Protocolo terapéutico de uso de benzodiacepinas y antipsicóticos

  2023cites this paper
• New Antipsychotic Prescribing Continued into Skilled Nursing Facilities Following a Heart Failure Hospitalization: a Retrospective Cohort Study

  2022cites this paper
• Psychosis in Alzheimer disease — mechanisms, genetics and therapeutic opportunities

  2022cites this paper
• Pharmacological Management of Apathy in Dementia

  2022cites this paper
• Non-clinical uses of antipsychotics in resource-constrained long-term care facilities: ethically justifiable as lesser of two evils?

  2022cites this paper
• Exercise interventions ameliorate neuropsychiatric symptoms in dementia: A meta-analysis

  2022cites this paper
• Managing Behavioral and Psychological Symptoms of Dementia (BPSD) in the Era of Boxed Warnings

  2022cites this paper
• Cancer care for people with dementia: Literature overview and recommendations for practice and research

  2022cites this paper
• Evidence-Informed Approach to De-Prescribing of Atypical Antipsychotics (AAP) in the Management of Behavioral Expressions (BE) in Advanced Neurocognitive Disorders (NCD): Results of a Retrospective Study

  2022cites this paper
• Signs and symptoms associated with a need for supervision in patients with Alzheimer's disease

  2022cites this paper
• Risks and benefits of current and novel drugs to treat agitation in Alzheimer’s disease

  2022cites this paper